CURING LOCALIZED IMMUNE CONDITIONS

beginning with Type 1 diabetes — built for much more

At Rezq Bio, our mission is to re-educate the immune system — not suppress it

We have engineered a platform that pairs two distinct delivery modalities with an indication-agnostic architecture, facilitating rapid expansion across autoimmune and transplant landscapes with minimal modification

Treatment Delivery Modalities

          iDC
        
Cell Therapy
An autologous dendritic cell therapy that has established human safety with negligible side effects

Microspheres
A microsphere delivery system that has demonstrated preclinical parity to our cell-based therapy

Clinical Applications

Monotherapy
Treating autoimmune disease directly, quieting localized inflammation
Type 1 Diabetes is our lighthouse indication, with IBD and other diseases where immune pathology is concentrated soon following

Combination Therapy
Shielding transplanted cells — maximizing graft survival and minimizing the systemic burden of traditional immunosuppressants
Islet cell grafts will be the first to be potentiated by our technology

T1D IS A global PROBLEM WITH NO SOLUTION

64k

New U.S. Diagnoses Annually

2M

Patients Currently in the U.S.

18M

Patients Worldwide by 2040

$85B

Economic Impact Globally

NO LONGEr A JUVENILE CONDITION

In a 2023 study from Johns Hopkins Bloomberg School of Public Health:

● Up to 62% of T1D cases develop in patients older than 20 (median 24 years)

● 37% of patients were diagnosed after 30 years

LACK OF EFFECTIVE TREATMENTS

There are no FDA-approved therapies for TID proven to…

● Prevent disease onset

● Arrest its progression or

● Restore insulin production safely

treatment options

T1D Treatment Approaches

Rezq's Approach

Treats localized problems locally…

Regional targeting avoids systemic effects

Leverages the immune system to address the inflammatory environment completely

Technology supports multi-disease treatment platform without therapeutic modification

Strong preclinical evidence to support immunosuppressant applications

Systemic Therapies

Significant side effects can offset effectiveness

Suppressed immunity to infection

Malignancy

Organ damage

Targeted Therapies

Offer precision with drawbacks

Narrow molecular or pathway focus does not address the problem completely

Disease specific, often with limited applicability

Varying degrees of systemic immunosuppression

Transplants / Implants

Cell transplant and stem cell technologies show promise

Require systemic and lifelong immunosuppressive therapy

Autoimmune attack still continues

Insulin Therapy

The standard of care is not a solution

Less than 1/3 of patients with T1D in the U.S. are consistently achieving target blood-glucose levels

Daily, lifelong insulin supplementation does not prevent comorbidities such as heart disease, stroke, nephropathy, blindness, foot amputations…

platform

We focus on dendritic cells as they are the regulator cells of the immune system. They can create an inflammatory or tolerant environment

We use our technological platform to convert dendritic cells from a mature (mDC) or inflammatory state, into an immature (iDC) or tolerogenic state

mDC

Environmental or other stimuli activate DCs - presenting co-stimulatory and other molecules on their surface causing T-Cell activation

mDCs can release inflammatory cytokines which can promote inflammation through different means

This state can promote immune dysregulation, and thus T1D as well as other autoimmune diseases and inflammation

iDC

iDCs have low presentation of co-stimulatory and other molecules on their surface leading to weak T-Cell activation properties

This benign state does not support or activate autoimmunity or inflammation

Importantly, tolerogenic DCs can convert an inflammatory state into a tolerant one

Our lead Phase 1B/2A ready autologous dendritic cell therapy is generated ex-vivo and has a strong safety profile with negligible side effects

Our treatment loaded microsphere delivery system replicates this approach in situ — loading therapies that generate tolerogenic dendritic cells locally, with equivalent preclinical performance to our cell therapy

By targeting the regional inflammatory environment rather than suppressing systemic immunity, our platform treats autoimmune disease directly and protects cellular grafts — with minimal modification

The result: a multi-condition, dual-delivery, dual-application foundation built for rapid expansion

Pipeline

Rezq’s pipeline is led by our cell therapy designed to treat early onset T1D. With promising in-human safety it provides a launching point for our multi-disease, dual-application and dual delivery method platform

Treatment Pipeline

Therapy Name

Indication

Discovery

Optimization

IND-Enabling

Phase 1A

Phase 1B/2A

RZQ-MC1

Early Onset Type 1 Diabetes

RZQ-MC1 is an autologous dendritic cell therapy, with negligle safety concerns found in a convincing Phase 1A trial. Rezq is planning to launch a Phase 1B/2A to treat early-onset T1D in the next year

RZQ-MC2

Colitis

RZQ-MC2 uses Rezq's autologous dendritic cell therapy to treat patients with Colitis and IBD related diseases. The preclinical work helped validate Rezq's regional treatment approach

RZQ-CC1

Various Indications

RZQ-CC1 leverages Rezq's immunosuppresion technologies to support other transplant and implant treatments to reduce or eliminate needs for systemic immunosuppression. Planned partnered preclinical studies will validate previous research findings

RZQ-MM*

Type 1 Diabetes

Rezq is advancing mulitple different microsphere payloads through preclinical testing to provide a small molecule based version of its localized approach enabling broader usage scenarios

people

We have built careers in healthcare and are passionate about curing T1D and autoimmune disease

People – Spotlight

Arjun Hattiangadi MBA, MS

CEO and Founder

tap for details

Doug Greene, MD

Head R&D

tap for details

Howard Foyt, MD, PhD

CMO

tap for details

Nick Giannoukakis, PhD

CSO and Founder

tap for details

Elina Linetsky, PhD

VP of Process, Dev and Mfg

tap for details

Don Very, PhD

Immunology Principal

tap for details

Seth Zimmerman, JD, MBA

VP of Finance

tap for details

Myra Frick

Clinical Coordinator

tap for details

Arjun Hattiangadi MBA, MS

CEO and Founder

tap for details

Doug Greene, MD

Head R&D

tap for details

Howard Foyt, MD, PhD

CMO

tap for details

Nick Giannoukakis, PhD

CSO and Founder

tap for details

Elina Linetsky, PhD

VP of Process, Dev and Mfg

tap for details

Don Very, PhD

Immunology Principal

tap for details

Seth Zimmerman, JD, MBA

VP of Finance

tap for details

Myra Frick

Clinical Coordinator

tap for details

Board and Advisory

We are fortunate to have an accomplished Board and Advisory that believe in our team, science and mission to treat autoimmune disease

Board & Advisors – v3

James Nolan

Board Chair

tap for details

Stan Marks, MD

Board Member

tap for details

Massimo Trucco, MD

Advisor and Founder

tap for details

David Finegold, MD

Advisor and Founder

tap for details

Orville Kolterman, MD

Advisor

tap for details

Philip Raskin, MD

Advisor

tap for details

Robert Pearlman

Advisor

tap for details

James Nolan

Board Chair

tap for details

Stan Marks, MD

Board Member

tap for details

Massimo Trucco, MD

Advisor and Founder

tap for details

David Finegold, MD

Advisor and Founder

tap for details

Orville Kolterman, MD

Advisor

tap for details

Philip Raskin, MD

Advisor

tap for details

Robert Pearlman

Advisor

tap for details